{{위키데이터 속성 추적}}
{{drugbox
| Verifiedfields = changed
| verifiedrevid = 476993112
| IUPAC_name = (''RS'')-[5-ethyl-4,6-dioxo-5-(pentan-2-yl)-1,4,5,6-tetrahydropyrimidin-2-yl]sulfanide sodium
| image = Sodium thiopental.svg
| width = 113
| alt = 1:1 mixture (racemate)
| image2 = Sodium-thiopental-3D-vdW-2.png

<!--Clinical data-->
| Drugs.com = {{drugs.com|monograph|thiopental-sodium}}
| pregnancy_category = 
| legal_AU = S4
| legal_US = Schedule III
| routes_of_administration = Oral, intravenous

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 5.5<ref>{{저널 인용|author=Russo H, Brès J, Duboin MP, Roquefeuil B |title=Pharmacokinetics of thiopental after single and multiple intravenous doses in critical care patients |journal=Eur. J. Clin. Pharmacol. |volume=49 |issue=1–2 |pages=127–37 |year=1995 |pmid=8751034 |doi= 10.1007/BF00192371|url= }}</ref>-26 hours<ref>{{저널 인용|author=Morgan DJ, Blackman GL, Paull JD, Wolf LJ |title=Pharmacokinetics and plasma binding of thiopental. II: Studies at cesarean section |journal=Anesthesiology |volume=54 |issue=6 |pages=474–80 |year=1981 |month=June |pmid=7235275 |doi= 10.1097/00000542-198106000-00006|url= }}</ref>
| excretion =

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 71-73-8
| CAS_supplemental = (sodium salt)<br/>76-75-5 (free acid) <!-- Also CAS verified -->
| ATC_prefix = N01
| ATC_suffix = AF03
| ATC_supplemental =  {{ATC|N05|CA19}}
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 9561
| PubChem = 3000714
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00599
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2272257
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 49Y44QZL70
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00714
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 738

<!--Chemical data-->
| C=11 | H=17 | N=2 | Na=1 | O=2 | S=1
| molecular_weight = 264.32 g/mol
| smiles = [Na+].O=C1NC(=S)/N=C(/[O-])C1(C(C)CCC)CC
| InChI = 1S/C11H18N2O2S.Na/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C11H18N2O2S.Na/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15;/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16);/q;+1/p-1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AWLILQARPMWUHA-UHFFFAOYSA-M
}}
'''티오펜탈 나트륨'''은 속효성 [[바비튜레이트]] [[전신 마취제]]이다. 이 제제는 기본적 건강관리 체제의 하한선을 제시하는 WHO-EM의 핵심 제제이다.<ref name="essentialWHO">{{웹 인용 | year = March 2005 | url = http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf | title = WHO Model List of Essential Medicines | format = PDF | publisher = World Health Organization | accessdate = 2006-03-12 | archive-date = 2007-02-12 | archive-url = https://web.archive.org/web/20070212145830/http://whqlibdoc.who.int/hq/2005/a87017_eng.pdf | url-status = dead }}</ref> 또한 이 제제는 미국에서 [[독살형]]에 쓰이는 세 제제 중에서 가장 많이 쓰인다.

== 같이 보기 ==
* [[펜토바르비탈]]
== 참고 문헌 ==
{{위키공용분류}}
{{각주}}

[[분류:AMPA 수용체 대항제]]
[[분류:GABAA 양성 알로스테릭 조절자]]
[[분류:전신 마취제]]
[[분류:글라이신 수용체 작용제]]
[[분류:수면제]]
[[분류:카이닌산 수용체 대항제]]
[[분류:니코틴 대항제]]
[[분류:진정제]]
[[분류:세계 보건 기구 필수 의약품]]
[[분류:화이자의 제품]]
[[분류:애브비의 제품]]
[[분류:유기산 나트륨염]]